Joint meeting with Biological and Medicinal Chemistry Sector of the Royal Society of Chemistry
This meeting is supported by:
.svg.png)
PROGRAMME
| 09.00 - 09.55 | Arrival, registration and coffee |
| 09.55 - 10.00 | Welcome and introduction |
|
Session 1 Chair: Nadia Ahmad |
|
| 10.00 - 10.40 | 1-1 Optimisation of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations Bill McCoull, AstraZeneca |
| 10.40 - 11.20 | 1-2 Targeted Delivery of Oligonucleotide Therapeutics using Bicycle® Peptide Technology
Megan St Denis, Bicycle Therapeutics |
| 11.20 - 12.00 | 1-3 Covalent fragment technologies for therapeutic target discovery and validation
Jake Bush, GSK |
| 12.00 - 13.00 | Lunch break and exhibitors |
|
Session 2 Chair: Giorgia Kidd |
|
| 13.00 - 13.40 | 2-1 Discovery of potent, selective classes of LIMK inhibitors for the treatment of FXS and AML Alex Baldwin, Cardiff University, Medicines Discovery Institute |
| 13.40 - 14.20 | 2-2 Reimagining the Drug Discovery Process in the AI Age James Dale, Pharmenable Therapeutics |
| 14.20 - 14.50 | Coffee break and exhibitors
|
|
Session 3 Chair: Daniel O Donovan |
|
| 14.50 - 14.55 | Introducing the SMR Early Career Researchers subcommittee |
| 14.55 - 15.30 | 3-1 Using Direct-to-Biology in a spectral shift-PoLiPa platform to enable fast fragment follow-up for A2a antagonists
Joe Mason, Domainex |
| 15.30 - 16.10 | 3-2 Discovery of ASTX295: A bone-marrow sparing MDM2 Antagonist. From concept to clinic
Steve Howard, Astex Pharmaceuticals |
| 16.10 - 16.50 | 3-3 Confounding factors in targeted degradation of short lived proteins Giorgia Kidd, University of Dundee, Centre for Targeted Protein Degradation |
| 16.50 - 17.00 | Closing comments and meeting close |